Breast cancer prognostic significance of some modified urinary nucleosides

Clinical significance and prognostic value of urinary nucleosides in breast cancer patients

“…This is in accordance with previous results [9,16]. Our data also revealed that the mean nucleoside concentrations from patients with benign breast tumors were significantly lower than those of breast cancer patients.…”

“…In recent years, clinical studies on the role of urinary modified nucleosides as biochemical markers of various types of cancer have been actively undertaken [1,[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]. Immunoassays [1,[8][9][10] and reverse phase high performance liquid chromatography (RP-HPLC) [11][12][13][14][15][16]23] have been extensively applied to determine modified nucleosides in urine. Recently, some preliminary studies have been published about urinary-modified nucleosides determined by micellar electrokinetic chromatography (MEKC) due to its high efficiency, high speed and small sample size requirement [14,15,[17][18][19][20]24,25].…”

Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control

“…Urinary excretion of methylated nucleosides, which results from increased turnover and degradation of RNA, especially from transfer ribonucleic acid (tRNA), has been shown to be excreted in increased amounts in the urine of patients with different types of tumours and AIDS (Nakano et al, 1993;Xu et al, 2000;Yang et al, 2004;Zheng et al, 2005). Elevated levels of modified nucleosides have been found in urine from patients with leukaemia and lymphoma (Rasmuson and Björk, 1995), cancer of the lung (McEntire et al, 1989), oesophagus (Masuda et al, 1993), breast (Rasmuson et al, 1987;Nakano et al, 1993;Sasco et al, 1996;Zheng et al, 2005), renal cell carcinoma (Koshida et al, 1985), ovarian cancer (Oerlemans and Lange, 1986), liver cancer (Yang et al, 2004), tumours of the bladder (Kvist et al, 1993), colon cancer (Holstege et al, 1986) and Hodgkin's disease (Martinow et al, 1998). One possible cause is the higher turnover rate of tRNA in tumour tissues than that in normal counterparts as demonstrated by Borek et al (1977).…”

“…For the quantification and identification of these nucleosides, immunoassays (Masuda et al, 1993;Ishiwata et al, 1995;Sasco et al, 1996), capillary electrophoresis (Yang et al, 2004;Zheng et al, 2005), column-switching or precolumn methodology (Boos et al, 1988) as well as high-performance liquid chromatography/mass spectrometry (Dudley et al, 2004) have all been applied. However, when a broad spectrum of modified nucleosides has to be determined, the preferred method is high-performance liquid chromatography (HPLC) (Lakings et al, 1977;Koshida et al, 1985;Oerlemans and Lange, 1986;Sander et al, 1986;Rasmuson et al, 1987;McEntire et al, 1989;Gehrke and Kuo, 1990;Schöch et al, 1990a, b;Kvist et al, 1993;Nakano et al, 1993;Topp et al, 1993;Rasmuson and Björk, 1995;Martinow et al, 1998;Xu et al, 2000;Yang et al, 2004).…”

“…The concentrations of modified nucleosides in urine, primarily degradation products of tRNA, have been regarded as potential indicators for the wholebody turnover of RNAs, suggesting them as possible markers for malignant diseases (Sander et al, 1986;Schöch et al, 1990a, b;Nakano et al, 1993;Topp et al, 1993). Sasco et al (1996) evaluated the prognostic significance of six urinary modified nucleosides in 68 breast cancer patients and found that excretion of 1-methylinosine and 1-methyladenosine was even further increased in patients with more advanced disease.…”